Daily non-political popular news in brief.
New details in schizophrenia treatment trial emerge
03-01-2007 · EurekAlert!Two new studies from the CATIE trial provide more insights into comparing treatment options, and to what extent antipsychotic medications help people with schizophrenia learn social, interpersonal and psychosocial skills. Quetiapine, and to some extent olanzapine, may be more effective than risperidone among patients who were originally taking, but had to discontinue, perphenazine -- an older, first generation antipsychotic medication. Patients taking antipsychotic medications, regardless of type, experience modest improvements in social, interpersonal and psychosocial skills.
Read more »
Keywords: details, schizophrenia, treatment, trial, emerge, detail
« Previous | Next »
Similar news on "New details in schizophrenia treatment trial emerge":
- Older medication may be more cost-effective for some patients with schizophrenia
12-01-2006 · EurekAlert!
A new study analyzing the economic implications of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) concludes that the older (first generation) antipsychotic medication perphenazine was less expensive and no less effective than the newer (second generation) medications used in the trial during initial treatment, suggesting that older antipsychotics still have a role in treating schizophrenia.
Similar news · Read more »
- Is there a role for serial outpatient drug infusions in advanced heart failure?
03-25-2007 · EurekAlert!
For patients with severe chronic heart failure, known as stage D or chronic decompensated heart failure (CDHF), hospitalization is frequent and treatment options are limited. The FUSION II trial (Follow-Up Serial Infusions of Nesiritide in Advanced Heart Failure) tested the benefit of a novel drug infusion regimen of serial administration of nesiritide (NES) versus placebo in outpatients with advanced heart failure and a primary endpoint of all cause mortality and cardiorenal hospitalizations.
Similar news · Read more »
- Major breakthrough toward the treatment of HIV/HAART-associated Lipodystrophy Syndrome
12-05-2007 · EurekAlert!
The HIV/HAART-associated Lipodystrophy Syndrome is a common side-effect of antiretroviral medications to treat HIV infection. Dr. Julian Falutz, director of the HIV Metabolic Clinic at the McGill University Health Center, and Dr. Steven Grinspoon, director at the Massachusetts General Hospital Program in nutritional metabolism are publishing the results of their recent clinical trial in the Dec. 6, 2007, issue of the New England Journal of Medicine.
Similar news · Read more »
- Pretty in Pictures: Details of molecular machinery gain Nobel
10-14-2006 · Science News Online
This year's Nobel Prize in Chemistry went to a researcher who determined the structure, in atomic detail, of RNA polymerase taken from yeast cells.
Similar news · Read more »
- Data show treatment with Remicade reduced hospitalizations for ulcerative colitis patients by half
10-23-2006 · EurekAlert!
Patients with UC treated with Remicade® (infliximab) had an approximate 50 percent reduction in mean number of hospitalizations per year compared with placebo, according to an analysis of long-term data from a Phase 3 clinical trial presented at the ACG meeting. Patients who responded and those who were in remission at one year had lower mean number of hospitalizations vs. non-responders through one year of treatment.
Similar news · Read more »
- Clinical trial data for Perforomist Inhalation Solution presented at International ATS Conference
05-21-2007 · EurekAlert!
New product recently approved by FDA for long-term maintenance treatment of COPD bronchoconstriction; data demonstrate first nebulized formoterol fumarate provides improved lung function comparable to dry powder formoterol, enhanced patient quality of life, and positive safety profile.
Similar news · Read more »
- Trial stops after stroke and mortality significantly reduced by blood
08-06-2007 · EurekAlert!
An international trial looking at the benefits of giving blood-pressurelowering medication to elderly patients has stopped early, afterresearchers observed significant reductions in overall mortality inthose receiving treatment.
Similar news · Read more »
- Ovation further advances development pipeline with new phase III epilepsy study
09-04-2007 · EurekAlert!
Ovation Pharmaceuticals is initiating a pivotal Phase III clinical trial for clobazam, a unique 1,5 benzodiazapine with significant anticonvulsant properties, as adjunctive treatment for patients with Lennox-Gastaut syndrome, one of the most severe forms of childhood epilepsy that frequently persists into adulthood. LGS is a rare and debilitating form of epilepsy. Clobazam represents one of five CNS launches Ovation expects over the next five years.
Similar news · Read more »
- Israeli scientists identify: Genes that affect responses of multiple sclerosis patients to copaxone
10-10-2007 · EurekAlert!
Getting the drug dosage correct can be a tricky exercise in trial and error in a disease like multiple sclerosis. Scientists from the Weizmann Institute and the Technion have identified two genes that affect a patient's response to the drug Copaxone, a finding which may help take the some of the guesswork out of treatment.
Similar news · Read more »
- Radiation plus chemo quadruples survival time for fatal brain cancer
10-29-2007 · EurekAlert!
Over four times as many patients with a rapidly fatal type of brain cancer, glioblastoma multiforme, who are treated with the chemotherapy drug temozolomide and radiation therapy, can live for four years after diagnosis, compared to those who receive only radiation treatment, according to updated results of a large, international trial presented at the Plenary I session on Oct. 29, 2007, at the American Society for Therapeutic Radiology and Oncology's 49th Annual Meeting in Los Angeles.
Similar news · Read more »
